Phospho-NF-kB p65 (Ser536) Antibody | Affinity Biosciences LTD|亲科生物官网

$Figure 5.| Analysis of signaling pathways. (A) Protein levels of NF‑κB P65, p‑P65, IKKβ and IκBα in the total cell fraction of control and co‑cultured Jurkat cells and (B) densitometric analysis of the western blot data.$

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4| Overexpression of uc.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 5|BB abrogates the activation of NFκB pathway in the testis of DM rats.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 7 | Effects of Huangqin decoction (HQD) on colonic expression levels of nuclear factor-kappa B (NF-kB) pathway proteins assessed by Western blot in dextran sulfate sodium (DSS)-induced colitis mice (A).

Phospho-NF-kB p65 (Ser536) Antibody - Supplemental Figure 7.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE S3 | miR-26a-overexpressing exosomes exert a similar effect as an NF-κB inhibitor in promoting axonal regeneration and inhibiting astrogliosis.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 9 | p65 phosphorylation at Ser536 is suppressed by HSV-1 UL2.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 Eriodictyol-induced apoptosis of glioma cells is mediated by the PI3K/Akt/NF-κB signaling pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 CD47 deficiency promotes HFD-induced nuclear factor-κB (NF-κB) activation and translocation.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 The effect of etanercept on the expressions of TRAF2, p38, P-p38, p65, P-p65 in B cells stimulated by BAFF and TNF-α.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 7 NF-κB/TWIST1 mediates the effect of S.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 2 Analysis of Interested Molecular Expression in Breast Tumor Tissues of Patients (A) Relative expression of miR-7, ESAM, and RELA were analyzed in breast tumor tissues and adjacent normal tissues of 12 patients by qRT-PCR.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4 The deficiency of Smad4 inhibited the inflammatory response in a cellular model of human insulin resistance.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4 Expression of ANX‐A1 (37 kDa), p‐NF‐κB p65, ICAM‐1, TNF‐α and IL‐1β.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3 Treatment with HP promotes apoptosis of Dami cells through the NF-κB/IL-17 pathway.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 8 Effects of OCOP and COP on the NF-κB pathway in DSS-induced mice (A) Representative Western blotting images of pIκBα, IκBα, cytoplasmic p65 and nuclear p65 (B–E) The protein expression levels of pIκBα, IκBα, cytoplasmic p65 and nuclear p65 in the NF-κB pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3 Nampt promoted LPS-induced inflammation in MC3T3-E1 cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Tumor necrosis factor-induced protein-8 (TIPE)-mediated activation of the PI3K/Akt pathway is involved in the modulation of DcR3 levels in HCT116 cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 8 Inhibition of TLR4/MAPK/NF-κB signaling pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3 AOPPs reduced phosphorylation of Akt and promoted the phosphorylation of P65.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 BE-BJO inhibited the activation of the NF-κB signaling pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Bovine miR-125b regulates the expression of NF-κB, TNF-α and IL-6 in LPS-induced MAC-T cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Electroacupuncture pretreatment ameliorates HMGB1 and phosphor-NF-κB expression in the microglia.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 |C-PC treatment suppresses the expression of NLRP3 inflammasome and NF-κB signaling pathway in lung tissues.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 2 | Effects of the RvE1 and LXA4 combination on NF-κB modification.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Rosiglitazone attenuates bone cancer pain (BCP) through the activation of proliferator-activated receptor-γ (PPAR-γ) to inhibit the nuclear factor-kappa B (NF-κB)/nod-like receptor protein 3 (NLRP3) inflammatory axis in spinal cord neurons.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Effects of Y-1 and Y-2 on NRK-52e cells’ inflammatory cytokines stimulated by sodium oleate with/without CD36 silences representative.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 8.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4| The deficiency of Smad4 inhibited the inflammatory response in a cellular model of human insulin resistance.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 9 Effects of PAR-1 knockdown on p-NF-κB p65 by western blot (a) as well as NF-κB p65 (b) and p-NF-κB p65 (c) by immunofluorescence in SH-SY5Y cells treated with high glucose.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Effects of KDM2B on TLR4, NF-κB p65 and NLRP3 expression levels in myocardial ischemia-reperfusion injury in rats.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 10 RBFOX1 affects the NF-κB and NRF2/HO-1 pathway in H/R-induced HK-2 cells.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 2 Punicalagin suppresses the TNF-α and IL-17A-induced IL-1β upregulation via inhibiting NF-κB activation and cleaved caspase-1 expression in vitro.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

$Figure 8 Curcumin relieved LPS-induced sepsis. (A) After the last 4-OHT injection, Rosa26LSL-MLS-Stat3 and Rosa26LSL-MLS-Stat3;UbcERT2Cre/+ mice were injected with curcumin prior to LPS. Survival was monitored every 6 - 12 h after injection. The data shown represent a combination of two independent experiments. Statistical comparison of survival was performed with a log-rank test. **, P < 0.01, *, P < 0.05. (B) Serum samples were obtained from these mice and subjected to ELISA to examine MCP-5 levels. (C-D) The serum levels of LDH and albumin were assessed. (E) Lung tissues were removed, and the percentages of macrophages were analyzed by flow cytometry. (B-E) The data are representative of one of two independent experiments. Significance was calculated using a two-way ANOVA. **, P < 0.01, * P < 0.05, n.s., not significant. (F) Rosa26LSL-MLS-Stat3 and Rosa26LSL-MLS-Stat3;LyzCre/+ mice were injected with 10 mg/kg curcumin prior to LPS (20 mg/kg). Survival was monitored every 6 - 12 h after injection. Statistical comparison of survival was performed with a log-rank test. **, P < 0.01, *, P < 0.05. (G) BMDMs of the indicated genotypes were treated with 8 μM curcumin for 20 h and incubated with either 100 ng/mL LPS (30 min) or 100 ng/mL IFN-α (1 h) before harvesting. The cells were harvested, lysed, and subjected to a Western blot analysis. The membranes were blotted with the indicated antibodies. (H) Cells were treated with 8 μM curcumin for 20 h and incubated with 100 ng/mL LPS for another 15 min. Nuclei and cytoplasmic fractions were extracted. The levels of the indicated proteins were analyzed by a Western blot analysis. (I) BMDMs were treated with curcumin. After 20 h, these cells were stimulated with or without 100 ng/mL LPS for 6 h before loading. BMDMs were then treated sequentially with BSA-conjugated palmitate, oligomycin, FCCP, and ETO as indicated. The data are representative of one of two independent experiments performed with n = 5. (J) 4-OHT-treated BMDMs were treated with curcumin for 20 h, and then, the BMDMs were exposed to 100 ng/mL LPS and 10 μmol/L MG132 for an additional 6 h before harvesting. The cell lysates were isolated, IP with an anti-CPT1a antibody and analyzed by a Western blot analysis using an anti-ubiquitin antibody. (G, H and J) The results shown are representative of one of three independent experiments. (K) Schematic representation of the mitochondrial STAT3-mediated increase in FAO in a USP50-dependent manner in the LPS-induced sepsis model. Upon the LPS stimulation, mitochondrial STAT3 could induce CPT1a stabilization by promoting USP50 expression and facilitating CPT1a-USP50 binding, leading to a switch from glucose to an increased reliance on FAO for ATP production, which, in turn, further enhanced NF-κB nuclear localization, leading to a great amount of cytokine production.$

Phospho-NF-kB p65 (Ser536) Antibody - Figure 8 Curcumin relieved LPS-induced sepsis.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Effect of MG activated CAP-SIRT1 pathway on NF-κB-mediated inflammatory response in rat macrophages.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 Curculigoside treatment alleviated osteoclast-associated gene expression in Ti-induced BMSCs.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 3.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 WKYMVm inhibited the ERK1/2 and NF-κB p65 signaling pathways and affected the p38 signaling pathway in microglial cells.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 6 Superoxide dismutase (SOD)@zeolite imidazolate framework-8 (ZIF-8) administration counteracted inflammation in the cochlea caused by noise exposure.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 Effect of irisin on IL-1β-induced activation of NF-κB signaling in SW1353 cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 Gal-3 inhibition reduced diabetes-induced macrophage infiltration and NF-κB p65 activation.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4 Cytoplasmic mtDNA markedly activated STING signalling.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 7 Nesfatin‐1 prevented activation of NF‐κB signaling in SCI mice.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 The expression degrees of HMGB1, TLR4, NF-κB, p-38 MAPK, and ERK1/2 proteins (x¯ ±s).

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 The effect of OBB on the TLR4/NF-κB signaling pathway in 5-FU-induced IM mice.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 The expression of inflammatory proteins in pneumonia mice after SH treatment.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 XFZYD inhibited the IKBα/NF-κB signaling in rat models with CPB-induced ALI.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Berberine regulated the expression of phosphorylated NF-κB and Nlrp3 in mice with ALI.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 BA improved the expressions of MYD88, p–NF–κBp65/NF-κBp65, p-IκBa/IκBa, TLR2, and TLR4 in rat lung tissue.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 mRNA and protein expression in knee joint and spleen of CIA rats.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 2 The NOD1/NF-κB signaling pathway was activated in the liver of piglets challenged with LPS.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 The BGF effects on levels of oxidative stress-related factors and inflammasome factors.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 2 chTERT activated the NF-κB signaling pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Effect of MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1 on nuclear factor-κB signaling in proatherogenic VSMCs.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 SHFM1 regulates the NF-κB signaling pathway in ESCC cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5 Relative expression levels of NF-κB pathway-related proteins were measured via western blot assay.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 4 Ox‐LDL/LPS activated ADAM17 to increase cleavage of mTIMD4 in macrophages.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 XNJY regulates the NF-κB/IκB-α pathway in PSD model rats.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 2 Gla ameliorated liver inflammation induced by ethanol via activating the NF-κB pathway in vivo.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 HSP90AA1 over-expression activates STAT1 and P65 in PK-15 and 3D4/2 cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 GALNT6 promotes the release of inflammatory factors and pyroptosis in PDAC cells.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3 Expression of regulated on activation, normal T-cell expressed and secreted protein in Caco2 cells in each group.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 Upregulated expression of TRAF6/NF-κB/HIF-1α/VEGF pathway in HPH that aggravated by Cul 5 further (A) The effect of hypoxia treatment for 4 weeks on Cul5/TRAF6/NF-κB/HIF-1α/VEGF pathway expression in lung tissues of mice, and reverse effect of pevonedistat.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Effects of AdipoRon on p65 and adenosine monophosphate-activated protein kinase (AMPK) phosphorylation under proinflammatory conditions.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 8 Western blot analysis of the proteins.

Phospho-NF-kB p65 (Ser536) Antibody - Fig 4 miR-328-3p affects the expression of NF-κB signaling pathway and inflammation-related molecules after OGD treatment.

Phospho-NF-kB p65 (Ser536) Antibody - Fig 3 HEX enhances barrier integrity and limits the NF-κB signaling pathway in MMECs.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 9.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 High-dose VC attenuated the inflammatory response in CLP-induced sepsis rats at 1d, 3d and 5d.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 3 OR11H1‐A63 increased GADD45G expression and activated the NF‐κB and MAPK pathways.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 BA alleviates pyroptosis and inflammation in the spinal cord tissue of SCI rats.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 6 Luteolin inhibits the activity of the AGE-RAGE signaling pathway.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

$Figure 2. ASFV A528R inhibits the NF-κB p65 phosphorylation downstream TLR8 signaling. (A) 293T cells grown in 12-well plate (3 × 105 cells/well) were transfected with A528R plasmid (0.25 µg, 0.5 µg), pTLR8 (0.5 µg) as indicated. Twenty-four hours post transfection, cells were stimulated with R848 (5 µg/mL) for 12 h, the expressions of p-p65, p65, A528R, and pTLR8 were analyzed by Western blotting. (B–D) 293T cells were transfected with A528R (0.25 µg, 0.5 µg) or vector (EV) control (0.5 µg), together with MyD88 (0.5 µg) (B), IKK-β (0.5 µg) (C), p65 (0.5 µg) (D). Twenty-four hours later, the expressions of p-p65, p65, A528R, MyD88, IKK-β, p65 were analyzed by Western blotting. (E) 293T cells grown in 12-well plate (3 × 105 cells/well) were transfected with A528R (0.25 µg, 0.5 µg), pTLR8 (0.5 µg). Twenty-four hours post transfection, cells were stimulated with R848 (5 µg/mL) for 12 h. Cell lysates were fractionated into cytoplasmic and nuclear extracts, and the protein levels of p65 and p-p65 in different fractions were analyzed by Western blotting. The histone-H3 and GAPDH were also shown as the nuclear and cytoplasmic markers, respectively.$

Phospho-NF-kB p65 (Ser536) Antibody - Figure 2.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7 Pretreatment with CH223191 eliminated the blocking effect of 5-HIAA on NF-κB signaling pathway The expression levels of representative proteins of the NF-κB pathway in mammary (A) and colonic (D) tissues were determined in three groups of mice.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 5.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - FIGURE 5 Bcl-2, P-Caspase-3, P-LC3B, P-NF-kB p65 antibody immunoreactivities of all groups.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 Expression of TLR4, and MAPK/NK-κB activation as well as expression of UAPs (OTR, CX43) in myomentrium of LPS induced preterm labor and PBS treated control group.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4.

Phospho-NF-kB p65 (Ser536) Antibody - Fig.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 11 Four hub genes (matrix metalloproteinase [MMP] 9, ATF3, CCL4, RELA) were upregulated in destabilization of the medial meniscus (DMM) mouse model.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 7.

Phospho-NF-kB p65 (Ser536) Antibody - Figure 4 NLRC5 suppresses the NF-κB pathway in vivo and in vitro.

产品:	磷酸化 NF-kB p65 (Ser536) 抗体
货号:	AF2006
描述:	Rabbit polyclonal antibody to Phospho-NF-kB p65 (Ser536)
应用:	WB IHC IF/ICC IP
文献验证:	WB, IHC, IF/ICC
反应:	Human, Rat, Monkey
预测:	Mouse, Pig, Bovine, Horse, Sheep, Dog
蛋白号:	Q04206
RRID:	AB_2834435

浏览相似产品>>

阻断肽(封闭肽)是特异性结合目标抗体和阻断抗体结合的多肽。这些多肽包含抗体识别的抗原表位。与阻断肽结合的抗体不再与靶蛋白上的表位结合。例如，在免疫印迹(WB)和免疫组化(IHC)中，通过比较被阻断抗体和未阻断抗体的染色，可以看到哪种染色是特异性的。

规格	价格	库存
50ul	RMB¥ 1300	现货
100ul	RMB¥ 2400	现货
200ul	RMB¥ 3200	现货

货期: 当天发货

联系销售

MSDS

说明书

COA

实验方案

WB Handbook

IHC Protocol

IF/ICC Protocol

产品描述

来源:

Rabbit

应用:

WB 1:500-1:2000, IHC 1:50-1:500, IP 1:100-1:500, IF/ICC 1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:

Human, Rat, Monkey

克隆:

Polyclonal

特异性:

Phospho-NF-kB p65 (Ser536) Antibody detects endogenous levels of NF-kB p65 only when phosphorylated at Serine 536.

RRID:

AB_2834435
引用格式: Affinity Biosciences Cat# AF2006, RRID:AB_2834435.

偶联:

Unconjugated.

纯化:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, sodium azide and glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

别名:

展开/折叠

Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NF kappa B p65delta3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; OTTHUMP00000233473; OTTHUMP00000233474; OTTHUMP00000233475; OTTHUMP00000233476; OTTHUMP00000233900; p65; p65 NF kappaB; p65 NFkB; relA; TF65_HUMAN; Transcription factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V rel avian reticuloendotheliosis viral oncogene homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); V rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65;

抗原和靶标

免疫原:

A synthesized peptide derived from human NF- kappaB p65 around the phosphorylation site of Ser536.

基因/基因ID:

RELA(5970)

描述:

NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm.

研究领域

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Antifolate resistance.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Substance dependence > Cocaine addiction.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer. (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway. (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway. (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation. (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). Gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. BLOOD, 2020 (PubMed: 32291445) [IF=21.0]

Application: IF/ICC Species: mouse Sample: BMDMs

Supplemental Figure 7.| TMAO induced NLRP3 expression by enhanced NF-κB nuclear localization. (A) Representative immunofluorescence staining of NF-κB (red: Alexa Fluor 594) in 300µM TMAO-treated BMDMs for 24h.Scale bar=25μm (B) Representative immunofluorescence image of p-NF-κB (red: Alexa Fluor 594) in BMDMs cultured with Triptolide (20nM), TMAO or TMAO+Triptolide for 24hrs. Scale bar=25μm.

2). Polydopamine as a biocompatible and precise mitochondrial targeted therapeutic platform for reversing myocardial ischemia-reperfusion injury. Bioactive Materials, 2025 [IF=20.3]

Application: WB Species: Rat Sample: H9C2 cells

Fig. 5. CPC inhibits cGAS-STING pathway activation. (A) Mechanism of CPC inhibiting the activation of cGAS-STING signaling pathway. (B) Immunofluorescence staining and colocalization quantification of DAPI/TOM20/dsDNA in H9C2 cells from different treatment groups. Cytoplasmic dsDNA is indicated by yellow arrow, scale bar: 20 μm. (C) Quantitative real-time PCR analysis of mtDNA: mtDNA content was normalized to nuclear DNA. (D) Determination of the level of cGAMP in H9C2 cells. (E–I) WB of cGAS-STING pathway-related proteins in H9C2 cells, including representative images and quantitative analysis of cGAS, P-STING/STING, P-NF-κB/NF-κB and P-IRF3/IRF3. (J) Determination of the level of IL-1β in H9C2 cells. (K) Determination of the level of IL-6 in H9C2 cells. (L) Immunofluorescence staining of DAPI/TOM20/dsDNA in heart tissue from different treatment groups, the cytoplasmic dsDNA is indicated by yellow arrow, scale bar: 20 μm and 10 μm. (M) The colocalization analysis of DAPI/TOM20/dsDNA in heart tissues: the intensity profiles of the fluorescence signals. (N) Representative images of cGAS and P-STING immunohistochemical staining in heart tissues of different treatment groups, scale bar: 50 μm. Data were expressed as mean ± SE. Statistical significance was performed by one-way ANOVA with Tukey post hoc test. (n = 3, ns: P > 0.05, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).

3). An anti-inflammatory and neuroprotective biomimetic nanoplatform for repairing spinal cord injury. Bioactive Materials, 2022 (PubMed: 35845318) [IF=18.9]

Application: WB Species: Mice Sample: spinal cord

Fig. 2 Macrophage phenotype regulation based on RA@BSA@Cur NPs. (a) The schematic illustration of RA@BSA@Cur NPs regulated macrophage polarization under LPS. (b) The immunofluorescence and quantification results of RAW264.7 cultured different BSA-related NPs in LPS condition. CD86+ M1 macrophage (yellow arrow) and CD206+ M2 macrophage (white arrow), nuclei (DAPI: blue). Scale bar, 50 μm. (c&d) The flow cytometry analysis and quantification results of RAW264.7 (gated on F4/80+) cultured different BSA-related NPs in LPS condition. (e) The macrophages' M1 inhibition and M2 promotion regulated by RA@BSA@Cur NPs may be through the NF-κB pathway. (f) The inflammatory factors IL-6, TNF-α, and IL-4 changes after RA@BSA@Cur treatment. (n = 3 independent samples). Statistical differences were determined by using the Analysis of Variance (ANOVA) with Bonferroni's multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, ns: no significant; a.u. means arbitrary unit).

4). Prussian Blue Nanozyme Featuring Enhanced Superoxide Dismutase-like Activity for Myocardial Ischemia Reperfusion Injury Treatment. ACS Nano, 2025 [IF=16.8]

5). RIG-I, a novel DAMPs sensor for myoglobin activates NF-κB/caspase-3 signaling in CS-AKI model. Military Medical Research, 2021 (PubMed: 34148549) [IF=16.7]

6). Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. Nature communications, 2024 (PubMed: 38167274) [IF=16.6]

7). Tetrahedral Framework Nucleic Acids Based Small Interfering RNA Targeting Receptor for Advanced Glycation End Products for Diabetic Complications Treatment. ACS Nano, 2023 (PubMed: 37751401) [IF=15.8]

8). Nonswellable Hydrogel Patch with Tissue-Mimetic Mechanical Characteristics Remodeling In Vivo Microenvironment for Effective Adhesion Prevention. ACS nano, 2024 (PubMed: 38932673) [IF=15.8]

9). An eNOS-like nanomaterial for specific reversal of cerebral ischemia-reperfusion injury. Nature Communications, 2025 [IF=15.7]

10). Hierarchical Targeting Nanodrug with Holistic DNA Protection for Effective Treatment of Acute Kidney Injury. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 39703158) [IF=15.1]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.

Phospho-NF-kB p65 (Ser536) Antibody - #AF2006

产品推荐

相关下载

MSDS

说明书

COA

实验方案

WB Handbook

IHC Protocol

IF/ICC Protocol

产品描述

抗原和靶标

研究领域

文献引用

限制条款